PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation
description
Transcript of PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation
PCSK9 Regulates LDLR Turnover Through Increased Intracellular
Degradation
Genetics PCSK9
PCSK9-Directed Therapies in Development
Alirocumab (SAR236553)Change in LDL-C at 2- and 4-Week Dosing Intervals on
Atorvastatin
Evolocumab (AMG 145) Change in LDL-C at 2- and 4-Week Dosing
Intervals on Statin Therapy
MENDELEvolocumab Monotherapy for Hypercholesterolemia
LAPLACE-TIMI 57 Evolocumab Combined With Statin for
Hypercholesterolemia
StatinsApproximate LDL-C Lowering Efficacy
ENHANCESimvastatin/Ezetimibe in FH
Effect of Alirocumab on LDL-C in Heterozygous FH
RUTHERFORDEffect of Evolocumab on LDL-C in Heterozygous
FH
GAUSSEvolocumab in Statin Intolerance
PCSK9-Directed Therapies in Development
OSLER Extension Study
OSLEREffect of Evolocumab on LDL-C after 52 Weeks
Clinical Utility of PCSK9 Inhibitors
Phase 3 Trials
Use of PCSK9 InhibitorsBased on Evidence or Definitive Outcomes Data?
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)